Detail akcie Bio Blast Pharma online

Business Summary: Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Enlivex Therapeutics Ltd revenues was not reported. Net loss decreased 26% to $5.3M. Lower net loss reflects Financial income increase from $11K to $1.2M (income), Loss on disposal group of assets held fo decrease of 86% to $29K (expense), Stock-based Compensation in GA decrease of 32% to $342K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.38 to -$0.22.